Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease

World Journal of Hepatology

Volumn 5, Issue 9, 2013, Pages 470-478

  Kostapanos, Michael S ^a   Kei, Anastazia ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Fenofibrate; Non alcoholic fatty liver disease; Peroxisome proliferator activated receptors; Steatohepatitis

Indexed keywords

EID: 84885769159     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i9.470     Document Type: Review

References (104)

1. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17 Suppl: S186-S190 [PMID: 12000605 DOI: 10.1046/j.1440-1746.17.s1.10.x]
2. Diakou MC, Liberopoulos EN, Mikhailidis DP, Tsianos EV, Burroughs AK, Elisaf MS. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol 2007; 42: 139-147 [PMID: 17327932 DOI: 10.1080/00365520601058395]
3. Cuadrado A, Orive A, García-Suárez C, Domínguez A, Fernández-Escalante JC, Crespo J, Pons-Romero F. Nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg 2005; 15: 442-446 [PMID: 15826485 DOI: 10.1381/0960892053576596]
4. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 162-168 [PMID: 20460906 DOI: 10.1159/000282081]
5. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8 Suppl 1: S4-S8 [PMID: 19381118 DOI: 10.1002/cld.27]
6. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic Fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45 [PMID: 23703888 DOI: 10.1093/aje/kws448]
7. Bellentani S, Saccoccio G, Masutti F, Crocé LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117 [PMID: 10644271 DOI: 10.7326/0003-4819- 132-2-200001180-00004]
8. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26 [PMID: 11296693 DOI: 10.1055/s-2001-12926]
9. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007; 132: 2191-2207 [PMID: 17498512 DOI: 10.1053/j.gastro.2007.03.055]
10. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004; 53: 1020-1023 [PMID: 15194655 DOI: 10.1136/gut.2003.027086]
11. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219 [PMID: 12717402 DOI: 10.1053/jhep.2003.50193]
12. Szczepaniak K, Person WB, Hadzi D. Experimental matrix isolation study and quantum-mechanics-based normalcoordinate analysis of the anharmonic infrared spectrum of picolinic acid N-oxide. J Phys Chem A 2005; 109: 6710-6724 [PMID: 16834024 DOI: 10.1021/jp058089o]
13. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241-246 [PMID: 10613753 DOI: 10.1002/hep.510310136]
14. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351 [PMID: 15864352 DOI: 10.1172/JCI23621]
15. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, Zalunardo B, Lirussi F, Alessandri C, Violi F. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90: 1578-1582 [PMID: 15598693 DOI: 10.1210/jc.2004-1024]
16. Abdeen MB, Chowdhury NA, Hayden MR, Ibdah JA. Nonalcoholic steatohepatitis and the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1: 36-40 [PMID: 17675901 DOI: 10.1111/j.0197-3118.2006.05523.x]
17. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, Lowell BB, Spiegelman BM. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 1998; 101: 1-9 [PMID: 9421459 DOI: 10.1172/JCI1411]
18. Tobin KA, Ulven SM, Schuster GU, Steineger HH, Andresen SM, Gustafsson JA, Nebb HI. Liver X receptors as insulinmediating factors in fatty acid and cholesterol biosynthesis. J Biol Chem 2002; 277: 10691-10697 [PMID: 11781314 DOI: 10.1074/jbc.M109771200]
19. Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 2005; 87: 81-86 [PMID: 15733741 DOI: 10.1016/ j.biochi.2004.11.008]
20. Lioudaki E, Ganotakis ES, Mikhailidis DP. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011; 17: 3632-3643 [PMID: 22074433 DOI: 10.2174/1381612117982 20945]
21. Zhang Y, Lu X, Hong J, Chao M, Gu W, Wang W, Ning G. Positive correlations of liver enzymes with metabolic syndrome including insulin resistance in newly diagnosed type 2 diabetes mellitus. Endocrine 2010, 38: 181-187 [PMID: 20972737 DOI: 10.1007/s12020-010-9369-6]
22. Marchesini G, Avagnina S, Barantani EG, Ciccarone AM, Corica F, Dall'Aglio E, Dalle Grave R, Morpurgo PS, Tomasi F, Vitacolonna E. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 2005; 28: 333-339 [PMID: 15966506]
23. Forlani G, Di Bonito P, Mannucci E, Capaldo B, Genovese S, Orrasch M, Scaldaferri L, Di Bartolo P, Melandri P, Dei Cas A, Zavaroni I, Marchesini G. Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest 2008; 31: 146-152 [PMID: 18362506]
24. Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity (Silver Spring) 2006; 14 Suppl 3: 121S-127S [PMID: 16931493 DOI: 10.1038/oby.2006.291]
25. Tominaga K, Fujimoto E, Suzuki K, Hayashi M, Ichikawa M, Inaba Y. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med 2009; 14: 142-149 [PMID: 19568858 DOI: 10.1007/s12199-008-0074-5]
26. Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 2009; 8 Suppl 1: S18-S24 [PMID: 19381120]
27. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009; 35: 277-287 [PMID: 19452403 DOI: 10.1055/s-0029-1222606]
28. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8 Suppl 1: S40-S43 [PMID: 19381123 DOI: 10.4254/wjh.v2.i4.139]
29. Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep 2009; 11: 50-55 [PMID: 19166659 DOI: 10.1007/s11894-009-0008-4]
30. Korantzopoulos P, Tzimas P, Kalantzi K, Kostapanos M, Vemmos K, Goudevenos J, Elisaf M, Milionis H. Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res 2009; 40: 582-589 [PMID: 20082873 DOI: 10.1016/ j.arcmed.2009.07.012]
31. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009; 205: 533-537 [PMID: 19159884 DOI: 10.1016/j.atherosclerosis.2008 .12.012]
32. Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev 2009; 10: 412-419 [PMID: 19413701 DOI: 10.1111/j.1467-789X.2009.00594.x]
33. Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 2009; 8 Suppl 1: S51-S59 [PMID: 19381125]
34. Kim HK, Park JY, Lee KU, Lee GE, Jeon SH, Kim JH, Kim CH. Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. Am J Med Sci 2009; 337: 98-102 [PMID: 19214024 DOI: 10.1097/ MAJ.0b013e3181812879]
35. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 1396-1402 [PMID: 18986848 DOI: 10.1016/j.cgh.2008.08.012]
36. Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007; 56: 443-444 [PMID: 17339254 DOI: 10.1136/gut.2006.106021]
37. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49: 80-86 [PMID: 19053049 DOI: 10.1002/hep.22575]
38. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]
39. Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643-1647 [PMID: 16696815 DOI: 10.1111/j.1365-2036.2006.02926.x]
40. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M, Chayama K. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-1718 [PMID: 19013295 DOI: 10.1016/j.metabol.2008.07.030]
41. Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T, Chayama K. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-a-lowering property. Dig Liver Dis 2012; 44: 492-496 [PMID: 22265683 DOI: 10.1016/j.dld.2011.12.013]
42. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-228 [PMID: 12201623 DOI: 10.1185/030079902125000787]
43. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-1922 [PMID: 21109302 DOI: 10.1016/S0140-6736(10)61272-X]
44. Kostapanos MS, Mikhailidis DP, Elisaf MS. Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit? Future Cardiol 2012; 8: 813-817 [PMID: 23176685 DOI:10.2217/fca.12.64]
45. Filippatos TD, Elisaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol 2011, 3: 265-267 [PMID: 22059109 DOI: 10.4254/wjh.v3.i10.265]
46. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005; 21: 1997-2006 [PMID: 16368051 DOI: 10.1185/030079905X75078]
47. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007; 193: 428-437 [PMID: 16911813 DOI: 10.1016/j.atherosclerosis.2006.07.010]
48. Hermans MP. Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD. Curr Cardiol Rev 2010; 6: 112-118 [PMID: 21532777 DOI: 10.2174/157340310791162686]
49. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093 [PMID: 9808609 DOI: 10.1161/01.CIR.98.19.2088]
50. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 2012; 1821: 809-818 [PMID: 22056763 DOI: 10.1016/j.bbalip.2011.10.016]
51. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790-793 [PMID: 9655393 DOI: 10.1038/31701]
52. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 2003; 101: 545-551 [PMID: 12393563 DOI:10.1182/ blood-2002-06-1762]
53. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 123-132 [PMID: 12829994 DOI: 10.1053/jhep.2003.50307]
54. Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 2011; 141: 603-610 [PMID: 21346097 DOI:10.3945/jn.110.135210]
55. Stienstra R, Mandard S, Patsouris D, Maass C, Kersten S, Müller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology 2007; 148: 2753-2763 [PMID: 17347305 DOI: 10.1210/en.2007-0014]
56. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39: 1286-1296 [PMID: 15122757 DOI:10.1002/hep.20170]
57. Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ?-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract 2012; 66: 843-853 [PMID: 22897461 DOI: 10.1111/j.1742-1241.2012.02972.x]
58. Filippatos TD. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovasc Drugs Ther 2012; 26: 245-255 [PMID: 22592524 DOI:10.1007/s10557-012-6394-0]
59. Filippatos TD, Tsimihodimos V, Kostapanos M, Kostara C, Bairaktari ET, Kiortsis DN, Elisaf MS. Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J Clin Lipidol 2008; 2: 279-284 [PMID: 21291744 DOI: 10.1016/ j.jacl.2008.06.001]
60. Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring) 2009; 17: 504-509 [PMID: 19023279 DOI: 10.1038/oby.2008.530]
61. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010; 95: 829-836 [PMID: 20061429 DOI: 10.1210/jc.2009-1487]
62. Hamilton SJ, Chew GT, Davis TM, Watts GF. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients. Clin Sci (Lond) 2010; 118: 607-615 [PMID: 20047560 DOI: 10.1042/CS20090568]
63. Genest J, Nguyen NH, Theroux P, Davignon J, Cohn JS. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J Cardiovasc Pharmacol 2000; 35: 164-172 [PMID: 10630748 DOI: 10.1097/00005344-200001000-00022]
64. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861 [PMID: 16310551 DOI: 10.1016/S0140-6736(05)67667-2]
65. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559 [PMID: 18539917 DOI: 10.1056/NEJMoa0802743]
66. Buldak L, Dulawa-Buldak A, Labuzek K, Okopien B. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. Int J Clin Pharmacol Ther 2012; 50: 805-813 [PMID: 22943927 DOI: 10.5414/CP201735]
67. Koh KK, Quon MJ, Shin KC, Lim S, Lee Y, Sakuma I, Lee K, Han SH, Shin EK. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis 2012; 220: 537-544 [PMID: 22153696 DOI: 10.1016/j.atherosclerosis.2011.11.018]
68. Li XM, Li Y, Zhang NN, Xie YH, Shi YQ. Combination therapy with metformin and fenofibrate for insulin resistance in obesity. J Int Med Res 2011; 39: 1876-1882 [PMID: 22117989 DOI: 10.1177/147323001103900531]
69. Shin SJ, Lim JH, Chung S, Youn DY, Chung HW, Kim HW, Lee JH, Chang YS, Park CW. Peroxisome proliferatoractivated receptor-alpha activator fenofibrate prevents highfat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens Res 2009; 32: 835-845 [PMID: 19644507 DOI: 10.1038/hr.2009.107]
70. Krysiak R, Labuzek K, Okopien B. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep 2009; 61: 1134-1145 [PMID: 20081249 DOI: 10.1016/j.regpep.2009.03.008]
71. Koh KK, Quon MJ, Lim S, Lee Y, Sakuma I, Lee YH, Han SH, Shin EK. Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. Atherosclerosis 2011; 214: 144-147 [PMID: 21075373 DOI:10.1016/j.atherosclerosis.2010.10.023]
72. Fatani S, Itua I, Clark P, Wong C, Naderali EK. The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage. Int J Gen Med 2011; 4: 211-219 [PMID: 21475632 DOI: 10.2147/IJGM. S17376]
73. Hong XZ, Li LD, Wu LM. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 2007; 34: 27-35 [PMID: 17201732 DOI: 10.1111/j.1440-1681.2007.04547.x]
74. Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, van Bilsen M, Hofker MH. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol 2006; 44: 732-741 [PMID: 16466828 DOI: 10.1016/j.jhep.2005.10.033]
75. Lalloyer F, Wouters K, Baron M, Caron S, Vallez E, Vanhoutte J, Baugé E, Shiri-Sverdlov R, Hofker M, Staels B, Tailleux A. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol 2011; 31: 1573-1579 [PMID: 21474829 DOI: 10.1161/ ATVBAHA.110.220525]
76. Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, Kim A, Yeon JE. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 2008; 23: 102-109 [PMID: 18171348 DOI: 10.1155/2012/757803]
77. Cong WN, Tao RY, Tian JY, Liu GT, Ye F. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci 2008; 82: 983-990 [PMID: 18417155 DOI: 10.1016/j.lfs.2008.01.022]
78. Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, Okanoue T. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 2006; 26: 613-620 [PMID: 16762007 DOI: 10.1111/ j.1478-3231.2006.01265.x]
79. Chan SM, Sun RQ, Zeng XY, Choong ZH, Wang H, Watt MJ, Ye JM. Activation of PPARa ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes 2013; 62: 2095-2105 [PMID: 23349482 DOI: 10.2337/db12-1397]
80. Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010; 6: 454-463 [PMID: 20567246 DOI: 10.1038/nrendo.2010.89]
81. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54: 280-290 [PMID: 21052978 DOI: 10.1007/s00125-010-1951-1]
82. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574 [PMID: 20228404 DOI: 10.1056/NEJMoa1001282]
83. Kondo K, Sugioka T, Tsukada K, Aizawa M, Takizawa M, Shimizu K, Morimoto M, Suematsu M, Goda N. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. Adv Exp Med Biol 2010; 662: 77-82 [PMID: 20204774 DOI: 10.1007/ 978-1-4419-1241-1_10]
84. Baron M, Leroyer AS, Majd Z, Lalloyer F, Vallez E, Bantubungi K, Chinetti-Gbaguidi G, Delerive P, Boulanger CM, Staels B, Tailleux A. PPARa activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. Atherosclerosis 2011; 218: 69-76 [PMID: 21529810 DOI: 10.1016/j.atheroscler osis.2011.03.009]
85. Villarreal-Molina MT, Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochi- mie 2012; 94: 2143-2149 [PMID: 22796520 DOI:10.1016/j.biochi.2012.06.030]
86. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14: 561-566 [PMID: 14624132 DOI: 10.1097/00041433-200312000-00003]
87. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33 [PMID: 14551151 DOI: 10.1161/01. ATV.0000099786.99623.EF]
88. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152: 113-118 [PMID: 15762194 DOI:10.1530/eje.1.01821]
89. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006; 101: 2629-2640 [PMID: 16952281 DOI: 10.1111/j.1572-0241.2006.00848.x]
90. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100 [PMID: 12840063 DOI: 10.1172/JCI17797]
91. Neumeier M, Weigert J, Schäffler A, Weiss TS, Schmidl C, Büttner R, Bollheimer C, Aslanidis C, Schölmerich J, Buechler C. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun 2006; 350: 731-735 [PMID: 17022944 DOI: 10.1016/j.bbrc.2006.09.101]
92. Walter R, Wanninger J, Bauer S, Eisinger K, Neumeier M, Weiss TS, Amann T, Hellerbrand C, Schäffler A, Schölmerich J, Buechler C. Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis. Exp Mol Pathol 2011; 91: 740-744 [PMID: 21946149 DOI: 10.1016/j.yexmp.2011.09.006]
93. Christou GA, Tellis KC, Elisaf MC, Tselepis AD, Kiortsis DN. High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment. Hormones (Athens) 2012; 11: 178-188 [PMID: 22801564 DOI: 10.1194/jlr.M029934]
94. Li P, Shibata R, Maruyama S, Kondo M, Ohashi K, Ouchi N, Murohara T. Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway. Am J Physiol Endocrinol Metab 2010; 299: E560-E566 [PMID: 20663986 DOI: 10.1152/ajpendo.00284.2010]
95. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-121 [PMID: 15591515 DOI:10.1136/gut.2003.037010]
96. Ma H, Gomez V, Lu L, Yang X, Wu X, Xiao SY. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24: 233-237 [PMID: 18713296 DOI:10.1111/j.1440-1746.2008.05548.x]
97. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339 [PMID: 17268472 DOI:10.1038/nm1557]
98. Rahman SM, Qadri I, Janssen RC, Friedman JE. Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J Lipid Res 2009; 50: 2193-2202 [PMID: 19502591 DOI:10.1194/jlr.M800633-JLR200]
99. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-883 [PMID: 16709309 DOI:10.1185/030079906X104696]
100. Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, De-Fronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007; 50: 1723-1731 [PMID: 17520238 DOI:10.1007/s00125-007-0698-9]
101. Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008; 40: 200-205 [PMID:18261709 DOI:10.1016/j.dld.2007.10.002]
102. Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990; 40: 260-290 [PMID: 2226216 DOI:10.2165/00003495-199040020-00007]
103. Thulin P, Rafter I, Stockling K, Tomkiewicz C, Norjavaara E, Aggerbeck M, Hellmold H, Ehrenborg E, Andersson U, Cotgreave I, Glinghammar B. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicol Appl Pharmacol 2008; 231: 1-9 [PMID: 18455211 DOI: 10.1016/j.taap.2008.03.007]
104. Kobayashi A, Suzuki Y, Kuno H, Sugai S, Sakakibara H, Shimoi K. Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. J Toxicol Sci 2009; 34: 377-387 [PMID: 19652460 DOI:10.2131/jts.34.377]